Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic total occlusions

Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic total occlusions

Aims To evaluate the outcomes of sirolimus-eluting stent (SES) implantation for the treatment of chronic total occlusion (CTO). Methods and results We identified 122 patients who underwent revascularization in CTO lesions with SES from April 2002 to April 2004 (SES group). A control group was compos...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European heart journal 2005-06, Vol.26 (11), p.1056-1062
Hauptverfasser: Ge, Lei, Iakovou, Ioannis, Cosgrave, John, Chieffo, Alaide, Montorfano, Matteo, Michev, Iassen, Airoldi, Flavio, Carlino, Mauro, Melzi, Gloria, Sangiorgi, Giuseppe M., Corvaja, Nicola, Colombo, Antonio
Format: Artikel
Sprache:eng
Schlagworte:
Angioplasty
Biological and medical sciences
Cardiology. Vascular system
Case-Control Studies
Chronic Disease
Coronary Angiography
Coronary Restenosis - prevention & control
Coronary Stenosis - therapy
Death, Sudden, Cardiac - etiology
Drug Implants
Female
Follow-Up Studies
Hospitalization - statistics & numerical data
Humans
Immunosuppressive Agents - administration & dosage
Male
Medical sciences
Middle Aged
Myocardial Infarction - etiology
Myocardial Revascularization
Occlusion
Prospective Studies
Restenosis
Revascularization
Sirolimus - administration & dosage
Stents
Survival Analysis
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aims To evaluate the outcomes of sirolimus-eluting stent (SES) implantation for the treatment of chronic total occlusion (CTO). Methods and results We identified 122 patients who underwent revascularization in CTO lesions with SES from April 2002 to April 2004 (SES group). A control group was composed of 259 consecutive patients with CTO lesions treated with bare metal stents (BMS) in the 24 months immediately before the introduction of SES (BMS group). At 6-month follow-up, the cumulative rate of major adverse cardiac events (MACE) was 16.4% in the SES group and 35.1% in the BMS group (P
ISSN:0195-668X
1522-9645
DOI:10.1093/eurheartj/ehi191